Clinical Trial Search

Primary: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) as Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 by the…

Primary: Safety Assessed by Development of Adverse Events and Dose-limiting Toxicity to Determine Maximum Tolerated Dose — 3; 3; 6; 0 Participants

Primary: Assessment of Baseline-adjusted Plasma Concentration-time Curves for ALA After a Single PDT Treatment Applying 3 Tubes of BF-200 ALA in Conjunction With the BF-RhodoLED®…

Primary: Change in VLDL-apoB100 Production Rate — 21.7; 14.9; 21.3; 17.2 mg VLDL apoB100 / kg body weight per day — p=0.65

Primary: Percentage of Words Identified Before and After Training — 49.7; 55.7 percentage of words presented

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1 Participants

Primary: Minimum Number of Vaccine Doses Created Using Participant Tumor Sample — 6 doses

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 2; 3; 1 Participants

Primary: Cmax of NAC After Single Dose Administration of Test and Reference — 2804.38; 3215.63 ng/mL — p=0.0136

Primary: Number of Participants Intubated During Hospitalization — 8; 25 Participants — p=0.297

Primary: Tmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) — 3.00; 9.00; 5.00 hours

Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)

Primary: Evaluation of the Safety of N-Rephasin® SAL200 in Healthy Human Volunteers — 1; 0; 2; 1 Participants

Primary: Total Source Organ Counts Based on Individualized Organ Volumes of Interest (VOIs) — 0.33530; 0.59398; 2.13730; 4.89330 Percentage of Injected Dose